Canadian psychedelic biotech company Cybin has partnered with Worldwide Clinical Trials, a global contract research organization, to develop new psychedelic-based treatment options for mental health conditions, including major depressive disorder.
Worldwide has expertise in managing clinical trials for mental health conditions and has successfully recruited patients for psychedelic studies. The collaboration aims to advance new medications from discovery to reality, with a focus on cardiovascular, metabolic, neuroscience, oncology, and rare diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.